This post was originally published on this site Treatment with Adcetris (brentuximab vedotin) is most effective in people with relapsed or refractory Hodgkin’s lymphoma who have chemotherapy-sensitive disease, and when used as consolidation therapy immediately after stem cell transplant, a study found. The findings were presented at the 2019 European Society for Medical Oncology (ESMO)…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Erleada Cuts Risk of Death by 25% in Localized Castration-resistant Prostate Cancer, Phase 3 Trial Finds
This post was originally published on this site Add-on treatment with Erleada (apalutamide) lowers the risk of death by 25% in men on androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastases, according to updated results of a Phase 3 trial. The research, “Apalutamide (APA) and Overall…
Gynecological Cancer Patients with Specific Wnt Mutations and High DKK1 Levels Respond Better to DKN-01, Trial Results Show
This post was originally published on this site Leap Therapeutics’s investigational therapy DKN-01, alone or in combination with Taxol (paclitaxel), leads to significantly better responses in women with relapsed endometrial or ovarian cancer whose tumors have high levels of the Dickkopf-1 (DKK1) protein, or specific mutations in the Wnt signaling pathway, according to results of a Phase 2…
Darzalex, Kyprolis, Dexamethasone Combo Extends Time to Disease Progression in Relapsed, Refractory Multiple Myeloma Patients, CANDOR Trial Results Show
This post was originally published on this site A combination of Darzalex (daratumumab), Kyprolis (carfilzomib), and dexamethasone increases the time to disease progression or death in multiple myeloma patients who already have received one to three prior therapies. With those results, the CANDOR Phase 3 trial (NCT03158688), co-sponsored by Amgen and Janssen, achieved its primary goal…
Tecentriq Prolongs Survival of Patients with Advanced Lung Cancer Beyond Chemo, Phase 3 Trial Shows
This post was originally published on this site Tecentriq (atezolizumab) prolongs the lives of patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) when administered as a first-line therapy, compared to chemotherapy, according to the interim analysis of a Phase 3 clinical trial. That finding was presented in a late-breaking presentation titled, “IMpower110:…
PINKTOBER Events at Hard Rock Promote Breast Cancer Awareness
This post was originally published on this site Marking 20 years of support for breast cancer awareness and research, Hard Rock International has kicked off a host of efforts for its annual “PINKTOBER” campaign. Presented every October in observance of Breast Cancer Awareness Month, Hard Rock’s cafes, hotels, casinos and Rock Shops will raise money for the…
LAS System May Fail to Identify Sarcoidosis Patients at Urgent Need of Lung Transplant, Study Finds
This post was originally published on this site The current scoring system used to assess the urgency of lung transplants, called LAS (lung allocation score), fails to predict the risk of death in people with sarcoidosis, a single center study suggests. The study “Mortality for sarcoidosis patients on the transplant wait list in the Lung…
Radiation Prior to CAR T-cell Therapy in Non-Hodgkin’s Lymphoma May Ease Side Effects, Study Suggests
This post was originally published on this site Treating non-Hodgkin’s lymphoma patients with radiation before giving them CAR T-cell therapy may lessen the likelihood of them experiencing toxic side effects, a small study suggests. This finding was detailed at the 2019 American Society for Radiation Oncology Annual Meeting, in the presentation “Induction Radiation Prior to Commercial Chimeric…
Opdivo Boosts Long-Term Survival of Advanced Lung Cancer Patients, Phase 3 Trials Show
This post was originally published on this site Opdivo (nivolumab) continues to increase the long-term overall survival of patients with advanced non-small cell lung cancer (NSCLC) compared to the chemotherapy Taxotere (docetaxel), according to pooled data from two Phase 3 trials. The findings were presented in an oral presentation, titled “Five-Year Outcomes From the Randomized,…
Focal Therapy, AuroLase, Shows Good Safety and Potential Effectiveness in Pilot Clinical Trial
This post was originally published on this site Nanospectra Biosciences‘ AuroLase Therapy, a focal therapy for prostate cancer that uses gold-silica nanoparticles, showed a good safety profile and evidence of successfully eliminating the cancer in a pilot clinical trial. Results were published in the journal PNAS, in the study, “Gold nanoshell-localized photothermal ablation of prostate tumors…
Fertility-Sparing Surgery Equally Effective as Radical Surgery in Early Stage Ovarian Cancer, Study Finds
This post was originally published on this site Surgical treatment aimed at preserving fertility is just as effective, in terms of survival, as more aggressive surgery in treating early-stage ovarian cancer, a new study suggests. The study, “Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort…
FDA Approves Darzalex Combo for Newly Diagnosed Multiple Myeloma Patients Eligible for Transplant
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab), in combination with Velcade (bortezomib), thalidomide and dexamethasone (collectively known as VTd), to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT). Darzalex is an antibody designed to recognize and block…